Shield Thera Share News (STX)

Shield Thera Information

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes

Get Live Data

5.75 -0.10 (-1.71%)

Bid:

5.70

Ask:

5.80

Spread: 0.10 (1.754%)

Market Cap: £61.50m

Last checked at -

Intraday Shield Thera Share Chart

REMOVE ADS

Shield Therapeutics sinks as strong performance marred by data issues

Wed, 21st Feb 2024 12:36

(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mistake in the company's previous prescription forecasts.

Shield is a commercial-stage pharmaceutical company, focused on its flagship Accrufer iron deficiency treatment. Shares in the company were down 49% at 2.90 pence each in London on Wednesday afternoon.

For the year ended December 31, Shield said it had delivered USD17.5 million in revenue, up nearly three-fold from USD6.2 million in 2022.

Shield said that its Accrufer sales partnership with Viatris Inc to create a 100-person sales team and launch new brand campaigns had been "notable".

Of its 2023 revenue, Accrufer sales contributed USD11.6 million, around three times that achieved in 2022.

The average net selling price for Accrufer also increased 21% between the first and second half of the year to a prescription price of around USD145.

Total prescriptions tripled over the year to around 77,000. However, this was markedly down from the company's previous forecasts of between 100,000 and 130,000.

Shield said that this was due to a mistake in the projection methodology used by its third-party data provider, which resulted in a significant overstatement of total prescriptions over the year. The company said it was working with its data provider to ensure that these data mistakes are not repeated, and will provide an additional update alongside its full results.

The company expects to publish its annual results in April.

Chief Executive Officer Greg Madison said: "The progress made in the market in 2023 has shown us that the opportunity for Accrufer continues to be significant. Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half...Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer the oral iron of choice for patients."

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com